Literature DB >> 23242442

Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.

Anna M Varghese1, Camelia S Sima, Jamie E Chaft, Melissa L Johnson, Gregory J Riely, Marc Ladanyi, Mark G Kris.   

Abstract

BACKGROUND: We hypothesize that among patients with lung cancers the KRAS/EGFR mutation profile and overall survival of collegiate smokers (former smokers who smoked between 101 lifetime cigarettes and 5 pack-years) are distinct from those of never smokers and former smokers with 15 pack-years or more.
METHODS: We collected age, sex, stage, survival, and smoking history for patients evaluated from 2004 to 2009 with advanced stage lung cancers and known KRAS/EGFR status. Mutation profile and overall survival were compared using Fisher's exact test and log-rank test, respectively.
RESULTS: Data were available for 852 patients with advanced-stage lung cancers with known KRAS/EGFR status, of which 6% were collegiate smokers, 36% were never smokers, and 30% were former smokers with 15 pack-years or more. The mutation profile of collegiate smokers (15% KRAS mutations, 27% EGFR mutations) was distinct from those of never smokers (p < 0.001) and former smokers with 15 pack-years or more (p < 0.001) and not significantly different from those of former smokers with 5 to 15 pack-years (p = 0.9). Median overall survival for collegiate smokers was 25 months, compared with 32 months for never smokers (p = 0.4), 33 months for former smokers with 5 to 15 pack-years (p = 0.48), and 21 months for former smokers with 15 pack-years or more (p = 0.63).
CONCLUSIONS: Collegiate smokers with advanced-stage lung cancers represent a distinct subgroup of patients with a higher frequency of KRAS mutations and lower frequency of EGFR mutations compared with never smokers. These observations reinforce the recommendation for routine mutation testing for all patients with lung cancers and that no degree of tobacco exposure is safe.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23242442      PMCID: PMC3534987          DOI: 10.1097/JTO.0b013e31827914ea

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  13 in total

1.  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

Authors:  Melissa L Johnson; Camelia S Sima; Jamie Chaft; Paul K Paik; William Pao; Mark G Kris; Marc Ladanyi; Gregory J Riely
Journal:  Cancer       Date:  2012-07-18       Impact factor: 6.860

2.  Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

Authors:  Qiulu Pan; William Pao; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

3.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

Authors:  DuyKhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Ennapadam S Venkatraman; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

4.  Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Authors:  Snjezana Dogan; Ronglai Shen; Daphne C Ang; Melissa L Johnson; Sandra P D'Angelo; Paul K Paik; Edyta B Brzostowski; Gregory J Riely; Mark G Kris; Maureen F Zakowski; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-09-26       Impact factor: 12.531

5.  Molecular signature of smoking in human lung tissues.

Authors:  Yohan Bossé; Dirkje S Postma; Don D Sin; Maxime Lamontagne; Christian Couture; Nathalie Gaudreault; Philippe Joubert; Vivien Wong; Mark Elliott; Maarten van den Berge; Corry A Brandsma; Catherine Tribouley; Vladislav Malkov; Jeffrey A Tsou; Gregory J Opiteck; James C Hogg; Andrew J Sandford; Wim Timens; Peter D Paré; Michel Laviolette
Journal:  Cancer Res       Date:  2012-06-01       Impact factor: 12.701

6.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

Authors:  Allan R Li; Dhananjay Chitale; Gregory J Riely; William Pao; Vincent A Miller; Maureen F Zakowski; Valerie Rusch; Mark G Kris; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

10.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

View more
  10 in total

1.  Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.

Authors:  Satu Mäki-Nevala; Virinder Kaur Sarhadi; Aija Knuuttila; Ilari Scheinin; Pekka Ellonen; Sonja Lagström; Mikko Rönty; Eeva Kettunen; Kirsti Husgafvel-Pursiainen; Henrik Wolff; Sakari Knuutila
Journal:  Lung       Date:  2016-02       Impact factor: 2.584

2.  Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Authors:  R Taylor Ripley; Robert R McMillan; Camelia S Sima; Saad M Hasan; Usman Ahmad; Feiran Lou; David R Jones; Valerie W Rusch; Nabil P Rizk; James Huang
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

3.  Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Authors:  Norihiro Yamaguchi; Paul A Vanderlaan; Erik Folch; David H Boucher; Hannah M Canepa; Michael S Kent; Sidharta P Gangadharan; Adnan Majid; Olivier N Kocher; Michael A Goldstein; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2013-08-07       Impact factor: 5.705

4.  Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.

Authors:  Jin Sung Jang; Adam Lee; Jun Li; Hema Liyanage; Yanan Yang; Lixia Guo; Yan W Asmann; Peter W Li; Michele Erickson-Johnson; Yuta Sakai; ZhiFu Sun; Hyo-Sung Jeon; Hayoung Hwang; Aaron O Bungum; Eric S Edell; Vernadette A Simon; Karla J Kopp; Bruce Eckloff; Andre M Oliveira; Eric Wieben; Marie Christine Aubry; Eunhee Yi; Dennis Wigle; Robert B Diasio; Ping Yang; Jin Jen
Journal:  Sci Rep       Date:  2015-05-18       Impact factor: 4.379

5.  Searching for Bacteria in Neural Tissue From Amyotrophic Lateral Sclerosis.

Authors:  Ruth Alonso; Diana Pisa; Luis Carrasco
Journal:  Front Neurosci       Date:  2019-02-26       Impact factor: 4.677

6.  [Clinical Features of EGFR Mutation Negative in Patients 
with Non-small Cell Lung Cancer and Brain Metastases].

Authors:  Yixiang Zhu; Ye Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-01-20

7.  The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013-2018).

Authors:  Noémie Letellier; Sam E Wing; Jiue-An Yang; Stacy W Gray; Tarik Benmarhnia; Loretta Erhunmwunsee; Marta M Jankowska
Journal:  Int J Environ Res Public Health       Date:  2022-09-03       Impact factor: 4.614

8.  Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis.

Authors:  Shanbo Zheng; Rui Wang; Yang Zhang; Yunjian Pan; Chao Cheng; Difan Zheng; Yihua Sun; Haiquan Chen
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

9.  The 150 most important questions in cancer research and clinical oncology series: questions 57-66 : Edited by Chinese Journal of Cancer.

Authors: 
Journal:  Chin J Cancer       Date:  2017-10-03

10.  Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.

Authors:  Wolfgang M Brueckl; H Jost Achenbach; Joachim H Ficker; Wolfgang Schuette
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.